Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KRAWT
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
FS001-VH4-VL1-VC-MMAE
|
|||||
| Synonyms |
FS001-VH4-VL1-VC-MMAE
Click to Show/Hide
|
|||||
| Organization |
FORESEEN TECHNOLOGY (BEIJING) CO., LTD.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.4
|
|||||
| Structure |
|
|||||
| Antibody Name |
FS001-huVH4-huVL1
|
Antibody Info | ||||
| Antigen Name |
Glypican-3 (GPC3)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.17 nM | Positive GPC3 expression (GPC3+++/++) | ||
| Method Description |
HuH7 2500cell/well were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added with a 3-fold dilution across 11 points, for the various ADCs. Cell proliferation was measured after 5 days exposure, 100ul Cell titer glo 2.0 to test IC50.
|
||||
| In Vitro Model | Adult hepatocellular carcinoma | HuH7 cells | CVCL_0336 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 1.1 nM | Positive GPC3 expression (GPC3+++/++) | ||
| Method Description |
HepG2 2500cell/well were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added with a 3-fold dilution across 11 points, for the various ADCs. Cell proliferation was measured after 5 days exposure, 100ul Cell titer glo 2.0 to test IC50.
|
||||
| In Vitro Model | Hepatoblastoma | HepG2 cells | CVCL_0027 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 207 nM | Negative GPC3expression (GPC3-) | ||
| Method Description |
CHO 2500cell/well were plated at set initial densities in 96 well flat bottom plates in the appropriate growth media. 24 hours later, dosing solutions were added with a 3-fold dilution across 11 points, for the various ADCs. Cell proliferation was measured after 5 days exposure, 100ul Cell titer glo 2.0 to test IC50.
|
||||
| In Vitro Model | Normal | CHO cells | CVCL_0213 | ||
References